Skip to content

Clinical Trial on the Alleviation of Hair Loss Symptoms by “CosmeRNA-ARI”

Clinical Trial on the Cosmetic Product “CosmeRNA-ARI” for the Alleviation of Hair Loss Symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0011054
Enrollment
57
Registered
2025-09-22
Start date
2024-11-25
Completion date
Unknown
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Cosmetic) : Through random assignment, subjects were instructed to use Product A (CosmeRNA-ARI, containing the active ingredient) or Product B (control product, without the active ingredient).

Sponsors

SKINMED
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - Volunteers between the ages of 18 and 54 diagnosed with androgenic alopecia - Subjects who will not use special hair products or undergo hair care or manipulation during the study period - Subjects who will maintain the same hairstyle and color as at the first visit throughout the study period - Subjects who understand the purpose and content of the study and voluntarily sign the informed consent form prior to participation - Healthy subjects without acute or chronic physical diseases, including dermatological disorders - Subjects who are able to comply with follow-up observations during the study period

Exclusion criteria

Exclusion criteria: - Subjects who do not wish to participate or who have not signed the informed consent form - Subjects with severe acute renal or cardiac diseases, or other chronic diseases (e.g., hypertension, diabetes) within the last 6 months that may affect the study results - Subjects who are pregnant, breastfeeding, or planning to become pregnant within 6 months - Subjects with psychiatric disorders - Subjects with infectious skin diseases - Subjects who have undergone surgical treatments for hair loss such as hair transplantation or scalp reduction - Subjects who have taken oral dutasteride or finasteride within the last 6 months - Subjects who have applied topical hair growth or anti-hair loss agents within the past month - Subjects who have taken any of the following medications within the past month: steroids, cytotoxic agents, vasodilators, antihypertensive agents, anticonvulsants, beta-blockers, bronchodilators, diuretics, spironolactone, cimetidine, diazoxide, cyclosporine, or ketoconazole - Subjects who have applied topical steroid preparations to the scalp within the past month - Subjects deemed unsuitable for application of the investigational product due to severe seborrheic dermatitis, scalp psoriasis, or scalp infection - Subjects with other forms of alopecia besides androgenic alopecia, such as alopecia areata, telogen effluvium, or traction alopecia - Subjects with nutritional deficiencies caused by excessive dietary restrictions or gastrectomy, or those taking nutritional supplements that may affect hair loss - Any other subjects deemed unsuitable for participation by the investigator

Design outcomes

Primary

MeasureTime frame
Phototrichogram (total number of hairs within the shaved area)

Secondary

MeasureTime frame
Researcher evaluation by photography;Survey evaluation by test subjects;Anagen/Telogen ratio

Countries

Korea, Republic of

Contacts

Public ContactMin Youl Chang

SKINMED

mychang195@gmail.com+82-42-5118-8437

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026